Clinical Trials Arena on MSN9d
AstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase III
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic ...
The Pharma Letter10d
Eneboparatide met primary Phase III endpoint, says AstraZeneca
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
MPR10d
Eneboparatide Shows Promise in Chronic Hypoparathyroidism
Eneboparatide is an investigational parathyroid hormone (PTH) receptor 1 agonist. By binding to a specific conformation of the PTH receptor 1, eneboparatide is expected to restore PTH function and ...
PharmExec10d
Phase III Trial Data Show Eneboparatide Normalizes Serum Calcium Levels in Chronic Hypoparathyroidism
In the Phase III CALYPSO trial, eneboparatide demonstrated statistical significance in achieving albumin-adjusted serum calcium normalization while eliminating the need for active vitamin D and oral ...
pharmaphorum5d
JPM kicks off with takeovers by J&J, Novartis, and MSD
Merck KGaA spin-out Calypso said that Novartis’ involvement ... plus an option on two other drug targets, and has a combined potential value of up to $4.165 billion for Argo, plus royalties ...
PipelineReview.com11d
Eneboparatide met primary endpoint of normalising serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial
LONDON, UK I March 17, 2025 I High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary ...
Nasdaq2mon
Nasdaq Calypso
Our cloud-enabled multi-asset solutions deliver a single source of truth across your business, simplifying operations, reducing risk, and enabling accelerated time to market. Drawing on decades ...